文献速递消化道肿瘤与早癌消化内镜

配对末端增强子分析与全基因组测序揭示胃腺癌中CCNE1和IGF2增强子劫持

Integrated paired-end enhancer profiling and whole-genome sequencing reveals recurrent CCNE1 and IGF2 enhancer hijacking in primary gastric adenocarcinoma.
PubMed 文献 · Gut · 2019-09-21

该研究整合11例原发性胃癌的配对末端H3K27ac ChIP测序增强子谱与200余例胃癌全基因组测序数据,鉴定约150个增强子相关结构变异,发现CCNE1和IGF2增强子劫持导致癌基因表达上调,提示增强子劫持是胃癌癌基因激活的常见机制。

要点

  • 配对末端增强子分析与WGS可系统鉴定胃癌中增强子相关结构变异。
  • CCNE1增强子劫持见于8%患者,与高表达及TAD边界破坏相关。
  • IGF2增强子结构变异在胃癌和结直肠癌中共同存在。

核心结论

  • 胃癌中增强子相关结构变异约150个,多数与靶基因表达上调相关。
  • CCNE1增强子劫持发生于8%患者,伴随高CCNE1表达和TAD边界破坏。
  • IGF2增强子结构变异在胃癌和结直肠癌中共同存在,提示常见非编码驱动改变。

研究设计与样本

  • 对11例原发性胃癌及匹配正常组织行配对末端H3K27ac ChIP测序,并结合200余例胃癌WGS数据。
  • 整合匹配RNA-seq数据识别增强子相关结构变异及转录改变。
  • 采用CRISPR/Cas9基因组编辑、4C-seq、Capture-C和Hi-C对候选变异进行功能验证。

主要发现

  • PeNChIP-seq/WGS在胃癌中鉴定约150个增强子相关结构变异。
  • 与靶基因失调相关的结构变异中63%与肿瘤表达升高相关。
  • CCNE1重排胃癌表现为CCNE1高表达、TAD边界破坏及新TAD相互作用。
  • IGF2增强子相关结构变异在胃癌中被观察到,此前已在结直肠癌中报道。

关键数值与推荐

  • CCNE1增强子相关结构变异发生于8%的患者。
  • 与靶基因失调相关的结构变异中63%与肿瘤表达增加相关。

临床怎么用

  • 对于胃癌患者,可考虑整合增强子谱与WGS以识别增强子劫持驱动的癌基因激活。
  • CCNE1重排胃癌可能提示高CCNE1表达及治疗抵抗相关驱动机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Genomic structural variations (SVs) causing rewiring of cis-regulatory elements remain largely unexplored in gastric cancer (GC). To identify SVs affecting enhancer elements in GC (enhancer-based SVs), we integrated epigenomic enhancer profiles revealed by paired-end H3K27ac ChIP-sequencing from primary GCs with tumour whole-genome sequencing (WGS) data (PeNChIP-seq/WGS). DESIGN: We applied PeNChIP-seq to 11 primary GCs and matched normal tissues combined with WGS profiles of >200 GCs. Epigenome profiles were analysed alongside matched RNA-seq data to identify tumour-associated enhancer-based SVs with altered cancer transcription. Functional validation of candidate enhancer-based SVs was performed using CRISPR/Cas9 genome editing, chromosome conformation capture assays (4C-seq, Capture-C) and Hi-C analysis of primary GCs. RESULTS: PeNChIP-seq/WGS revealed ~150 enhancer-based SVs in GC. The majority (63%) of SVs linked to target gene deregulation were associated with increased tumour expression. Enhancer-based SVs targeting CCNE1, a key driver of therapy resistance, occurred in 8% of patients frequently juxtaposing diverse distal enhancers to CCNE1 proximal regions. CCNE1-rearranged GCs were associated with high CCNE1 expression, disrupted CCNE1 topologically associating domain (TAD) boundaries, and novel TAD interactions in CCNE1-rearranged primary tumours. We also observed IGF2 enhancer-based SVs, previously noted in colorectal cancer, highlighting a common non-coding genetic driver alteration in gastric and colorectal malignancies. CONCLUSION: Integrated paired-end NanoChIP-seq and WGS of gastric tumours reveals tumour-associated regulatory SV in regions associated with both simple and complex genomic rearrangements. Genomic rearrangements may thus exploit enhancer-hijacking as a common mechanism to drive oncogene expression in GC.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Ooi WF, Nargund AM, Lim KJ, et al. Integrated paired-end enhancer profiling and whole-genome sequencing reveals recurrent CCNE1 and IGF2 enhancer hijacking in primary gastric adenocarcinoma. Gut. 2019. PMID: 31542774. doi:10.1136/gutjnl-2018-317612

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。